INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $21,000 | -69.6% | 367 | -78.4% | 0.00% | -66.7% |
| Q2 2021 | $69,000 | +68.3% | 1,700 | +7.5% | 0.00% | 0.0% |
| Q3 2020 | $41,000 | +485.7% | 1,582 | +274.0% | 0.00% | +200.0% |
| Q1 2020 | $7,000 | -73.1% | 423 | -42.5% | 0.00% | -50.0% |
| Q4 2019 | $26,000 | +188.9% | 736 | -35.7% | 0.00% | +100.0% |
| Q3 2019 | $9,000 | -62.5% | 1,145 | -39.0% | 0.00% | -50.0% |
| Q2 2019 | $24,000 | +500.0% | 1,878 | +501.9% | 0.00% | – |
| Q1 2019 | $4,000 | -50.0% | 312 | -57.8% | 0.00% | -100.0% |
| Q4 2018 | $8,000 | +300.0% | 739 | +396.0% | 0.00% | – |
| Q2 2017 | $2,000 | -83.3% | 149 | -80.1% | 0.00% | -100.0% |
| Q1 2017 | $12,000 | -60.0% | 748 | -62.9% | 0.00% | -66.7% |
| Q4 2016 | $30,000 | -69.7% | 2,016 | -43.6% | 0.00% | -66.7% |
| Q1 2016 | $99,000 | – | 3,574 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |